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Abstract: Periventricular leukomalacia (PVL) is the most frequent cause of cerebral palsy 
and other intellectual disabilities, and currently there is no treatment. In PVL, glutamate 
excitotoxicity (GME) leads to abnormal oligodendrocytes (OLs), myelin deficiency, and 
ventriculomegaly. We have previously identified that the combination of transferrin and 
insulin growth factors (TSC1) promotes endogenous OL regeneration and remyelination in 
the postnatal and adult rodent brain. Here, we produced a periventricular white matter 
lesion with a single intracerebral injection of N-methyl-D-aspartate (NMDA). Comparing 
lesions produced by NMDA alone and those produced by NMDA + TSC1 we found that: 
NMDA affected survival and reduced migration of OL progenitors (OLPs). In contrast, 
OPEN ACCESS 
Brain. Sci. 2013, 3 1462 
 
mice injected with NMDA + TSC1 proliferated twice as much indicating that TSC1 
supported regeneration of the OLP population after the insult. Olig2-mRNA expression 
showed 52% OLP survival in mice receiving a NMDA injection and increased to 78% 
when TSC1 + NMDA were injected simultaneously and ventricular size was reduced by 
TSC1. Furthermore, in striatal slices TSC1 reduced the inward currents induced by NMDA 
in medium-sized spiny neurons, demonstrating neuroprotection. Thus, white matter loss 
after excitotoxicity can be partially rescued as TSC1 conferred neuroprotection to 
preexisting OLP and regeneration via OLP proliferation. Furthermore, we showed that 
early TSC1 administration maximizes neuroprotection. 
Keywords: premature birth; excitotoxicity; periventricular leukomalacia; white matter 
regeneration and repair; central nervous system repair; transferrin; insulin and IGF-1. 
 
1. Introduction 
Myelin is the essential fatty membrane that provides insulation to nerve fibers in the brain and 
spinal cord. In addition, myelin ensures the normal and adequate transmission of electrical signals 
from the brain or spinal cord to specific parts of the body and vice versa. Motor, sensory and 
integrative functions depend on the rapid, seamless conduction of nerve impulses along these 
myelinated nerve fibers [1]. In the developing brain, oligodendrocytes (OLs) are cells that form and 
maintain myelin throughout life. The cells are generated during perinatal life, and immature OLs are 
particularly vulnerable to insults, such as lack of oxygen. The impairment of OL development leads to 
intellectual and lifelong disabilities. Currently, treatments for myelin disorders are limited to reducing 
the inflammatory responses induced by hypoxia or glutamate toxicity and alleviating the symptoms, 
but little repair and gain-of-function are achieved. In the developing brain, OL maturation occurs 
perinatally, and immature OLs are particularly vulnerable. 
Myelin loss can result from myelin damage, such as that observed in multiple sclerosis (MS) or 
after brain or spinal cord injury. The lack of myelin could also be inherited, such as in  
Pelizaeus-Merzbacher, a leukodystrophy that reflects all known types of mutations and gene 
duplication in the proteolipid gene (PLP). Both types of myelin deficiencies are progressive and lead to 
dysfunction, paralysis and often death. Due to improved neonatal intensive care, the number of low 
birth weight (<1500 g) infants that survive is increasing [2,3]. Approximately 13 million premature 
infants are born worldwide every year, of which 90% survive beyond infancy. Premature infants, 
however, are extremely vulnerable to brain injury, and ~5%–10% of the survivors develop cerebral 
palsy and 40%–50% develop cognitive and behavioral deficits. The pattern of perinatal brain injury is 
age-dependent, e.g., while in full-term infants the cerebral cortex is predominantly affected through 
neuronal loss, in premature infants cerebral white matter injury (WMI) is more frequent. [4]. An array 
of brain injuries is included under the umbrella of cerebral WMI, of which periventricular 
leukomalacia (PVL) is one of the most severe forms [5]. Neuroimaging studies indicate that the most 
predominant type of PVL is diffuse WMI, resulting from the disrupted maturation of OL progenitors 
(OLPs), leading to hypomyelination [6,7]. Perinatal WMI is a leading cause of cognitive and 
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functional disability and is detected in a significant percentage of preterm human infants.  
Prematurity is often the most important risk factor for brain injury because the white matter is formed 
in the perinatal period, thus becoming the primary target of hypoxia-ischemia lesions resulting in PVL 
and germinal matrix/intraventricular hemorrhage, associated with a loss of gray matter [2–4,8]. 
Injury to both gray and white matter is the primary focus for improving neurological outcomes in 
survivors [9]. Several factors contribute to WMI and PVL, among which is an immature vascular 
system in the deep periventricular regions of the brain, making this organ vulnerable to cerebral 
ischemia. It is thought that in preterm infants, blood flow is low; consequently, any decrease in 
peripheral blood pressure exposes the brain to hypoxic-ischemic episodes, nonetheless, the evidence 
supporting this belief is scarce. Hypoxic-ischemic events trigger free radical formation and increase 
extracellular glutamate released from injured axonal processes, with a concomitant decreased uptake 
by astrocytes. OLs express functional glutamatergic receptors of the N-methyl-D-aspartate  
(NMDA)-subtype, and OLPs and pre-OLs are sensitive to both oxidative stress and glutamate-induced 
excitotoxicity [10–13]. Moreover, NMDA receptors are involved in OL death following ischemia [14,15]. 
Animal models mimicking PVL have been developed, facilitating the identification of the primary 
pathways that lead to OL cell death and WMI [12,13]. 
Previously, using a proteolipid protein rodent mutant, the myelin-deficient (md) rat, we showed that 
the failure of OLs to mature reflects myelin deficiencies [16]. We also showed that in cell culture,  
md OLPs express markers synthesized by more mature OLs. However, these markers were not 
expressed in vivo [17], suggesting that an adequate trophic environment may promote further 
maturation of OLs in these mutants. We then compared the ontogenetic profile for transferrin (Tf) 
gene expression in md mutants with that of unaffected rat pups through Northern blot analysis and  
in situ hybridization. Surprisingly, the synthesis of this early marker of OLs [18,19] was not observed 
in mutant OLs, while synthesis was normal in the choroid plexus, the second source of Tf in the central 
nervous system (CNS). Next, we demonstrated that a single apo-transferrin intraparenchymal injection 
administered to P5 rat pups enabled mutant OL to synthesize myelin basic protein (MBP) and myelin, 
indicating that Tf affects mutant OL maturation, regardless of its source; thus, Tf is an essential factor 
for myelination [20]. However, the md rat has a severe hypomyelinated CNS, and therefore, we sought 
to determine whether treatment with Tf in combination with other factors, would increase myelination. 
Using run-off transcription, we showed that Tf up-regulates the transcription of the MBP gene [21] and 
that it synergizes with IGF-1 increasing myelination. We named the combination of IGF-1 and Tf 
“TSC1”. This mixture promotes the maturation of endogenous OLs, facilitating the myelination of 
axons in the myelin deficient rat. Considering the adverse events leading to lifelong disabilities in the 
brain of premature neonates, in the present study, we investigated the potential preclinical therapeutic 
use of TSC1 to reduce excitotoxic injury and preserve the integrity of motor pathways in a model of 
PVL induced by intracerebral NMDA injection. 
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2. Experimental Section 
2.1. Animals and Intraparenchymal Injection Procedures 
Nestin-GFP mice [22] were bred at the University of California Los Angeles (UCLA, Los Angeles, 
CA, USA) in a restricted access, temperature-controlled vivarium under a 12 h:12 h light:dark cycle, 
with access to food and water ad libitum. Postnatal day four (P4) nestin-GFP mice pups were used. 
Each experiment consisted of three time points and five conditions: Non-treated mice, Saline, NMDA, 
NMDA + TSC1 simultaneously injected (N + TSC1 0 day) and NMDA + injection of TSC1 delayed  
3 days (N + TSC1 3 day). The stereotaxic intraparenchymal injections in brain, collection and 
sectioning of tissues for the characterization of cell phenotypes were performed as described [23]. 
Assessment of cellular stress was monitored through HSP-32 expression. We used 6 mice  
per condition. Three separate experiments were performed to assess the effects of NMDA alone or 
with TSC1 on endogenous OLP survival, proliferation and maturation. Intraparenchymal injections 
were performed according to previously described methods [23,24]. 
Briefly, nestin-GFP P4 pups were injected as follows. Ophthalmology microsurgery instruments 
and a stereotaxic apparatus with an adjustable adapter for small (newborn) animals were used. The 
animals were anesthetized with halothane and placed on a stereotaxic frame for the intraparenchymal 
administration of the cells with a Hamilton syringe. The injection coordinates were 1.2 mm lateral 
(right) and 0.7 mm caudal to Bregma. The needle was inserted 2.5 mm deep into the corpus callosum 
(CC). The control group consisted of nestin-expressing mice that received saline injections, using the 
same procedures. We performed unilateral grafts. The total volume of the injected factors was 1.5 μL. 
2.2. Induction of Glutamate Excitotoxicity (GME) 
We induced excitotoxicity in the GFP-nestin mice through the stereotaxic injection of NMDA into 
the CC. A single unilateral injection was performed on P4 mice as previously described [23]. 
2.3. Preparation of Trophic Factors 
The stock solutions were prepared in saline, and the TSC1 cocktail was also prepared in saline. 
2.4. Collection and Examination of the Samples 
Brain collection and sectioning for the characterization of cell phenotypes was performed as 
previously described [23]. To determine the effectiveness of the treatment, OLs and myelin were 
determined through the expression of cyclic nucleotide 3′-phosphohydrolase (CNPase). Cell 
proliferation was determined using Ki67, a marker of cellular proliferation, in combination with cell 
and stage specific markers for OLs. 
2.5. Measurements of the Lateral Ventricles 
Para-coronal 20 μm frozen sections were rinsed and mounted for lateral ventricle measurements. 
The area of ipsilateral “IL” vs. contralateral “CL” ventricles was obtained using LSM-Meta software 
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(Zeiss, Jena, Germany), and the difference was calculated in μm2. The data were converted to  
a percentage of the area, with respect to the contralateral ventricle. 
2.6. In Situ Hybridization 
Non-radioactive in situ hybridization for Olig2 was performed as previously described [23,25].  
The cells were counted using the interactive AxioVision Rel 4.6 program from Zeiss. 
The immunofluorescence procedures were performed as previously described [23,26]. Briefly, 
cultures were fixed with 4% paraformaldehyde. Samples were blocked for 1 h in 1% BSA  
(Sigma-Aldrich, Buchs, Switzerland), 0.3% Triton X-100 (Sigma-Aldrich), and 10% normal goat or 
donkey serum in PBS. Primary antibodies were diluted in carrier solution (1% BSA and 0.3% Triton 
X-100 in PBS) and incubated overnight at 4 °C. After washing with PBS, secondary antibodies were 
incubated for 1 h at room temperature, washed with TBS and mounted. Samples were imaged using 
the LSM 510 META confocal microscope (Zeiss) and analyzed with the Axiovision software (Zeiss). 
2.7. Myelin Staining for Frozen Sections: Spielmeyer’s Method 
Staining was performed using hematoxylin for 10–24 h, followed by rinsing in distilled water.  
The tissues were subsequently differentiated in 2.5% ferric ammonium sulfate solution, washed 
thoroughly for 2 h, followed by dehydration and mounting [27]. 
2.8. Stereology 
For stereology, brain sections were 28 μm thick. We used an Axio-Imager M2 (Zeiss) microscope 
equipped with the Stereo-Investigator software [Micro Bright Field (MBF) Inc., Williston, VT, USA]. 
The entire ventricular region (of the ipsilateral ventricle) was selected and imaged using a 5× objective 
and the Cavalieri Probe (MBF). 
2.9. Examination of the Neuroprotective Effects of TSC1 against NMDA Excitotoxicity 
For these experiments, brain slices were incubated in artificial cerebrospinal fluid (ACSF) or in 
ACSF supplemented with TSC1 prior to the acute exposure to NMDA. Striatal medium-sized spiny 
neurons (MSNs) were recorded using the patch-clamp technique, and the responses were evoked 
through electrical stimulation or bath application of NMDA (50–100 μM). Responses were compared 
in control slices (incubated in vehicle) and in slices incubated for 1 h in TSC1 solution. The amplitude 
of the response was evaluated using pClamp software (Molecular Devices, Sunnyvale, CA, USA). 
Coronal slices of 300 μm thickness were used. Whole-cell patch clamp recordings were obtained from 
neurons in the dorsal striatum. The cells were visualized through infrared-differential interference 
contrast (IR-DIC) microscopy and identified according to somatic size and basic membrane properties. 
The patch pipette (4–6 MΩ) contained a Cs-methanesulfonate (CsMeth) internal solution composed of: 
CsMeth 125 mM, NaCl 4 mM, KCl 3 mM, MgCl2 1 mM, EGTA 9 mM, HEPES 8 mM,  
MgATP 5 mM, TrisGTP 1 mM, disodium phosphocreatine 10 mM and leupeptin 0.1 mM (pH 7.2;  
270–280 mOsm/L) for recording in voltage clamp mode. The basic membrane properties were 
determined in cells perfused in standard ACSF at room temperature using the membrane properties 
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function within Clampex 8.2 (Molecular Devices). To evoke synaptic currents, a monopolar glass 
stimulating electrode (patch-pipette filled with ACSF, impedance ~1 MΩ) was placed in the deep 
cortical layers or white matter approximately 200–300 μm from the recorded cell. The cell membranes 
were voltage clamped at +40 mV to measure NMDA synaptic responses. When NMDA was applied in 
the bath, cell membranes were held at −70 mV. 
2.10. Statistical Analysis 
Quantitative data are expressed as the means ± SE. Comparison of mean values between multiple 
groups was evaluated using ANOVA followed by a post hoc Tukey HSD multiple comparison test 
where data obtained with the various treatments were compared either to their respective saline control 
or non-treated samples within the same age group. Significance was assumed when p ≤ 0.05. Student’s 
t test was used to analyze electrophysiological data. 
3. Results 
3.1. Effect of TSC1 on Ventriculomegaly 
The wall of the ventricles and subventricular region is the source of uncommitted neural progenitors 
both in the perinatal and the adult brain. Therefore, we determined the impact of NMDA in this region. 
We examined para-coronal sections to measure the ventricular size of GFP-nestin transgenic mice 
either untreated or injected with saline, NMDA alone, NMDA + TSC1 injected simultaneously, or 
NMDA followed by a delayed (3 days) injection of TSC1. Frozen sections (28 μm) were cut, washed, 
and mounted to be examined under the AxioVision microscope (Zeiss) equipped with the Stereo 
Investigator software (MBF). The volume of the ipsilateral ventricle was obtained using the  
Cavalieri Probe (MB field) (data are shown in Figure 1). The values from six adjacent coronal sections 
per time point, per mouse were obtained from three separate experiments. The mean values of these six 
sections were considered the value per mouse, per treatment for its respective experiment. Seven days 
after intraparenchymal injections, the animals treated with NMDA alone showed 82% larger ipsilateral 
ventricle (ILV; injected hemisphere) with respect to the contralateral ventricle (non-injected 
hemisphere). When NMDA was injected with TSC1 simultaneously (N + TSC1 sim), a reduction in the 
ventricle enlargement was observed; the ILV was 64% larger than the CLV (Figure 1). Upon insult, an 
acute inflammatory response that interferes with the beneficial effects of TSC1 is typically observed. 
Thus, we also examined whether a delayed injection of TSC1 would increase the neuroprotective 
effect if injected after cell death and the active inflammatory events occur within hours after the insult. 
We observed that the enlargement of the ILV was reduced but to a lesser extent in mice receiving a  
3-day delayed TSC1 injection when compared to mice that got the combined treatment simultaneously 
(Figure 1). 
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Figure 1. The enlargement of the ventricle after excitotoxicity is decreased with a single 
dose of TSC1. Seven and 35 days after injection of the specific treatments para-coronal,  
28 μm frozen sections were rinsed and mounted for stereological measurements. The volume 
of the entire ipsilateral (IL) ventricular region was selected and imaged using a 5× objective 
and the Cavalieri Probe (MBF) obtained in μm3. Data represent measurements of 6 adjacent 
coronal sections per time point from three separate experiments. The diagram shows  
a coronal section and the arrow points at the injection site (IS). Values are expressed as  
mean ± SEM of three independent experiments. p ≤ 0.05 vs. controls. All differences across 
treatments were significant. Abbreviations: P5 = Postnatal day five; PI = post injection day. 
 
3.2. Effects of TSC1 on OL (Oligodendrocyte) Proliferation 
We used the marker Ki67 to assess cell proliferation. One day after NMDA treatment (PI-1),  
the cell loss was considerable after NMDA injection, showing on average 70% of cells expressing 
CNPase in the subventricular zone (SVZ). At this time point, in the SVZ non-treated mice displayed 
some cells expressing CNPase as cells may have already migrated into the parenchyma, and 30% of 
the total number of cells were Ki67-positive. Mice treated with NMDA alone showed basically  
an almost total demise of cells 24 h after the injection in the SVZ, showing only 30% of the total cell 
number observed in non-treated mice. Among the surviving cells, most were CNPase-positive and only 
a small fraction was positive for Ki67 (Figure 2). The subsequent time points, post-injection days 14 
and 35, showed a reduction in both Ki67 and CNPase and the total number of cells in the SVZ.  
The total number of cells in mice injected with TSC1 alone at 24 h after the injection was equivalent to 
that in non-treated mice. Nonetheless, most of these cells proliferated, as shown by the location of 
Ki67, and few cells were CNPase-positive. Thirty-five days after TSC1 injection, most cells in the 
SVZ were CNPase-positive and only a fraction of these cells expressed Ki67. When both NMDA and 
TSC1 were injected simultaneously, the survival of CNPase-expressing cells present at the time of the 
excitotoxic insult was evident, while Ki67 labeling was reduced compared with non-treated mice at  
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an equivalent age. Seven days after treatment, almost no CNPase-expressing cells were observed in the 
SVZ, from which most cells were progenies, showing co-expression of Ki67/CNPase. At 1 and 7 days 
after treatment (PI 1 and PI 7), most CNPase-expressing cells were Ki67-negative, suggesting that 
these cells were present prior to administration of N + TSC1 and these cells were the predominant 
population in the SVZ at these time points. At PI 35, many cells were present in the SVZ but not 
labeled with either marker. Most CNPase- and Ki67-expressing cells were absent from this region, 
suggesting that most OLs had migrated into the parenchyma by this time point. Interestingly, when 
NMDA was injected at P4, followed by an injection of TSC1 3 days later, the total number of cells, 
those CNPase-positive cells and progenies labeled with Ki67, was higher with respect to that found in 
mice injected with NMDA + TSC1 simultaneously, as shown in Figure 2. 
Figure 2. Cell loss in the subventricular zone (SVZ) is partially rescued in the presence of 
TSC1 via cell survival or cell proliferation. Double immunofluorescence: cells expressing 
the proliferation marker Ki67 were found in this region at early time points in the presence 
of TSC1. Some cells co-expressed the two markers (Ki67/CNPase). In contrast, when  
N-methyl-D-aspartate (NMDA) was injected alone there was a dramatic reduction of the 
total number of cells. Green bars represent the total number of cells (i.e., 100% or the total 
number of cells counted in that field. Numbers for saline and non-treated mice were very 
close with no significant differences. Values are expressed as mean ± SEM of the counts of 
9 fields per area from three independent experiments. p < 0.05 vs. controls. All differences 
with respect to non-treated mouse brains as well as, across treatments were significant.  
P5 = Postnatal day five; PI = post injection day.  
 
3.3. Olig2 Expression 
We subsequently examined the expression of the transcription factor Olig2 through in situ 
hybridization as an indicator of the survival and migration of OLPs across treatments. The examination 
of sagittal sections at 14 days after the injection of the various agents showed that saline-injected mice 
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displayed a large number of Olig2-positive cells in the CC (Figure 3A) and a reduced number in  
the SVZ, indicating that the vast majority of OLPs had previously migrated to the CC.  
In animals injected with NMDA alone, the number of Olig2-expressing cells in the CC was reduced to 
approximately 6% (20 cells) of the total number of cells present in mice injected with saline  
(562 cells). Nonetheless, there were more Olig2-expressing cells in the SVZ than in animals  
injected with saline. Interestingly, after the NMDA + TSC1 injection, the cumulative number of  
Olig2-expressing cells, in both the CC and the SVZ, was greater than that of mice injected with 
NMDA alone (520 cells vs. 322 cells), suggesting that the migration of Olig2-expressing cells was not 
disrupted with NMDA treatment in the presence of TSC1 (Figure 3G). 
Figure 3. Panel (A–F). More Olig 2 expressing cells survive after NMDA exposure in the 
presence of TSC1. Examples of expression of the transcription factor Olig2 in the corpus 
callosum (CC) and SVZ 14 days after injection. Animals injected with saline displayed a 
large number of Olig2-positive cells in the CC (A) and a reduced number in the sub-ventricular 
zone (SVZ, D) suggesting that the vast majority of OLP had already migrated to the CC. 
(B) The CC of NMDA injected mice showed fewer cells and less intensely labeled cells 
while some intensely labeled cells were found in the SVZ (E). (C) the CC of the mouse 
injected with NMDA + TSC1 showed an extensive area containing Olig2-mRNA, this 
particular section shows the injection site (IS) devoid of Olig2-expressing cells but 
surrounded by intensely labeled OL progenitors. (F) Some Olig2-expressing cells were still 
present in the SVZ. (C) View of the injection site at the level of the CC of a mouse  
co-injected with NMDA and TSC1. The intensity of the label was low and the number of 
cells appeared reduced in both regions when compared to saline injected mice.  
(G) Quantitative data of Olig2-expressing cells. In animals injected with NMDA alone, the 
total number of Olig2-expressing cells in the CC and SVZ was reduced when compared to 
the total number of cells present in mice injected with saline. In contrast, there were more 
Olig2-expressing cells in the SVZ, than in animals injected with saline. Interestingly, with 
the N + TSC1 injection the total number of Olig2-positive cells in the CC and the SVZ was 
partially restored to 78% and almost to an equal distribution in the SVZ and the CC, 
suggesting that Olig2 positive cell migration was not disrupted by NMDA in the presence 
of TSC1. Values are expressed as mean ± SEM of the counts of 6 fields per area from three 
independent experiments. p ≤ 0.05. All differences across treatments were significant. 
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3.4. Myelination after Treatment 
The aim of this study was to determine at a qualitative level whether myelination could be restored 
after an excitotoxic insult using TSC1. Thirty-five days after treatment, we examined parasagittal  
brain sections obtained from mice receiving the various treatments. The Spielmeyer’s myelin staining 
method was used. We observed that, similar to the ILV of mice injected with NMDA alone or with 
NMDA + TSC1, the third ventricle was also enlarged. However, the proportion of enlargement was 
reduced in the presence of TSC1, whether injected simultaneously or after a 3-day delay. In mice 
treated with NMDA alone some regions where tissue was spared appeared devoid of myelin.  
In contrast, mice treated with NMDA + TSC1 showed more myelinated fibers in the CC and the 
striatum demonstrating the extensive neuroprotective effect of TSC1 (Figure 4). 
Figure 4. Myelination is partially rescued from excitotoxicity by TSC1. Representative 
para-sagittal brain sections (28 μm thick) stained with the Spielmeyer’s method for  
frozen sections. These views show (A) the myelination pattern with saline treatment  
40 days post-injection (PI). The extent of tissue damage, ventricle enlargement, and myelin 
loss in mice treated with NMDA (B) and its recovery with TSC1 (C) treatment. Moreover, 
NMDA treated mice showed areas where tissue was spared in the CC and CPu but there 
was not myelin staining. In contrast, mice treated with TSC1 showed nice myelinated 
fibers indicating that after the excitotoxic insult functional OLs developed and actively 
myelinated axons. The arrow points to a bundle of myelinated axons in the CPu of a mouse 
treated with NMDA + TSC1 simultaneously. In contrast, the same region of mice injected 
with NMDA alone did not show myelinated axons. The variability within each treatment 
group, consisting of 6 animals, was minimal based on low magnification examination as 
shown in Figure 4. 
 
3.5. Expression of the Stress Protein HSP-90 in Acute Brain Slices 
Coronal slices were exposed to either NMDA alone or pre-incubated for 1 h to 2 h in TSC1 and 
subsequently exposed to NMDA. After electrophysiology as shown (Figure 5), slices were fixed and 
examined through double immunofluorescence for the cell stress marker heat shock protein 90  
(HSP-90) and the OL marker cyclic nucleotide 3′-phosphohydrolase (CNPase). The results showed 
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that HSP-90 was expressed in the CC white matter in NMDA-treated mice but not in non-treated slices 
(Figure 6A–D vs. Figure 6E–L respectively). Those slices that were pre-incubated with TSC1 presented 
a clear expression of HSP-90 at the level of the cell soma and processes but not along axonal fibers. 
CNPase expression was observed and not all CNPase positive cells expressed HSP-90. In contrast, 
slices treated with NMDA without pre-incubation in TSC1 showed a diffuse distribution of HSP-90 
preferentially along the fibers expressed in mini-compartments like “puncta” and only few  
inter-fascicular cells were clearly seen expressing this stress protein but not CNPase (Figure 6F,G). 
Figure 5. Neuroprotection of Medium-sized Spiny Neurons (MSNs). Upper traces 
represent responses of striatal MSNs evoked by electrical stimulation (0.2 mA, 0.1 ms 
duration) of cortical inputs. Recordings were obtained with patch electrodes in voltage 
clamp mode (holding voltage at +40 mV). Control trace is a NMDA receptor-mediated 
response recorded in normal ACSF solution and isolated pharmacologically by adding  
2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX, 10 μM) and 
Bicuculline (10 μM). The trace on the right is from another cell recorded after the slice was 
incubated for 1 h in TSC1 solution (2 μL/mL). Lower traces show responses to bath 
application of NMDA (100 μM) in ACSF (left) or after incubation for 1 h in TSC-1. Notice 
that the NMDA responses were significantly reduced compared to control conditions. 
Calibration bars apply to both traces. 
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Figure 6. Acute NMDA exposure elicits the expression of HSP-90 in the CC and TSC1 
neutralizes the NMDA effect. Coronal brain slices 300 μm thick were used for the acute 
treatment of NMDA alone or in slices pre-incubated with TSC1. After electrophysiology, 
slices were fixed and immunolabeled for the cell stress marker HSP-90 and the OL  
marker CNPase. (A–D) representative views of untreated slices, neither nestin (A) nor  
CNPase-expressing cells (C-arrowheads) were labeled for HSP-90 (B-circle). (D) merged 
image. After acute NMDA, CNPase-positive OL expressed HSP-90 (E–F). Moreover, cells 
that were not labeled for either of the two markers also expressed HSP-90 (F,G-thin arrows 
and circle). In slices pre-incubated with TSC1 followed by acute NMDA treatment (see 
methods for details) (I–L) the majority of CNPase-positive cells did not express  
HSP-90 (K). Nestin-positive cells did not express HSP-90 in the presence of TSC1  
(I-circle). Some cells co-expressed CNPase and HSP-90 (J,K and L-open arrows). Insets 
show higher magnification views of the cells pointed by open arrows in (J) and (L). 
Arrowhead points to a CNPase-positive cell (K) that co-expresses HSP-90 (L). The inset in 
(J) shows an example on the colocalization of both HSP90 and CNPase both, in the cell 
body and processes (K,L). Calibration bar in (I) corresponds to 50 μm.  
 
3.6. Coronal Views of the Caudate Putamen in Nestin-GFP Mouse Slices: Acute Treatment 
After electrophysiology, coronal brain slices (300 μm thickness) were fixed and examined by 
double immunofluorescence for the cell stress marker HSP-90 and cyclic nucleotide 3′-phosphohydrolase 
(CNPase), an oligodendrocyte marker. The double staining showed that HSP-90 was not expressed in 
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non-treated slices. In contrast, HSP-90 was expressed as “puncta” mainly along myelin tracks. Some 
OLs recognized by CNPase co-expressed HSP-90 in NMDA treated slices. Slices pre-incubated in 
TSC1 had HSP-90 expressing cells that co-expressed CNPase, but the myelin tracks were not labeled by 
the stress protein, suggesting neuroprotection through TSC1 (Figure 7). 
Figure 7. Acute NMDA elicits the expression of HSP-90 in the CPu and TSC1 neutralizes 
the NMDA effect. Views of the CPu of 300 μm coronal slices used for the acute treatment 
of NMDA alone or in slices pre-incubated with TSC1. After electrophysiology, slices were 
fixed and immunolabeled for the cell stress marker HSP-90 and the OL marker CNPase. 
HSP-90 was expressed in some cells located in the CPu white matter. Non-treated slices 
(A–D) displayed nestin-expressing cells that were negative for HSP-90 (B-empty circle). 
Slices directly exposed to NMDA (E–H); showed colocalization of nestin and HSP-90 (E,F) 
and few cells co-express the three markers (open arrows). CNP-expressing cells lost 
processes or expression of CNPase in their processes. Slices incubated with TSC1 prior to 
NMDA. TSC1 appeared to maintain the tissue in a mild stage of stress with fewer  
nestin-expressing cells co-expressing HSP-90 (panel I) and increased number of  
CNPase-positive OL (K). Arrowheads show cells co-expressing HSP-90 and CNPase (K). 
Insets show detail of the label distribution of the cell marked with arrowheads, the merged 
view allows for the visualization of HSP-90 in the cell soma while CNPase is distributed in 
the cell body and numerous cell processes (L). K-inset shows a healthy OL that did not 
express HSP-90 (I-circle). 
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3.7. TSC1 Decreases NMDA-Induced Currents 
To examine the mechanisms through which TSC1 rescued some of the impairments produced by 
NMDA injections, we performed electrophysiological experiments using brain slices. Bath application 
of NMDA (50–100 μM) induced inward currents in all striatal MSNs examined (n = 16, 8 controls and 
8 TSC1-treated). Most cells (n = 6) recorded after 1–2 h incubation in TSC1 showed a reduction in 
NMDA currents compared with the controls, 1 cell showed no change and 1 cell treated with TSC1 
showed a slight increase (20%). The average percent reduction was 63% (t = 2.55, p < 0.02). As bath 
application affects both synaptic and extrasynaptic NMDA receptors, we also tested the effects of 
TSC1 incubation in a pair of MSNs. The cells were held at +40 mV and the responses were evoked by 
electrical stimulation of the CC. The cell incubated in TSC1 showed much smaller NMDA currents, 
confirming the neuroprotective effects of TSC1 (Figure 5). 
4. Discussion 
Injury or developmental damage to the white matter during formation in the immature brain leads to 
substantial motor, cognitive, and learning deficits. Premature birth is a major cause, and the initial 
insult may be followed by secondary and tertiary mechanisms, resulting in further deterioration of the 
brain structure and function [28]. It has been suggested [28] that these tertiary mechanisms of damage 
include persistent inflammation and epigenetic changes that can be modulated from being deleterious 
to becoming an opportunity for CNS repair. This reasoning has prompted research aimed at designing 
new therapies to treat individuals suffering from PVL and cerebral palsy. The goal of the present study 
was to evaluate endogenous repair of the immature brain in a mouse model of PVL. Based on the 
results from our previous work on myelin repair in dysmyelinating and demyelinated adult  
mice [23,26,29], we explored the therapeutic potential of TSC1 using a mouse model of white matter 
injury, as most commonly observed in premature infants. NMDA receptors are expressed in 
developing OL cell processes, and these receptors mediate excitotoxic injury [16]. We evaluated 
different parameters: ventriculomegaly, cell proliferation, expression of OL markers Olig2 and 
CNPase, the extent of myelination, and excitotoxic responses. 
Ventriculomegaly occurs in the premature newborn [30]. Following transient excitotoxicity in the 
neonatal brain, a series of events evolve temporally and spatially, leading to long-lasting disabilities. 
Without diminishing the importance of cell replacement therapies via transplantation, our recent efforts 
have been focused on the activation of endogenous neural regeneration to foster endogenous repair 
mechanisms via activation of progenitor cells to promote myelination. Cerebral palsy is a major health 
problem caused by brain damage during pregnancy, delivery, or the immediate postnatal period. 
Perinatal stroke, intraventricular hemorrhage, and asphyxia are the most common causes of neonatal 
brain damage. PVL is predominantly observed in premature infants and is the most common 
predecessor of cerebral palsy [28]. OLP treatment via transplantation has proven effective in restoring 
injured organs and tissues in animal models. Our data showed that TSC1, injected simultaneously with 
NMDA or three days after the excitotoxic insult, considerably reduced the extent of ventricular 
enlargement, with a concomitant increase in CNPase-expressing cells. 
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4.1. Proliferation of OLs after Treatment 
We used the proliferation marker Ki67 as an analog of BrdU in combination with the enzyme  
CNPase. We selected CNPase to identify OLs because it allows for the visualization of OL cell bodies. 
CNPase accounts for ∼2%–5% of the total protein in the CNS myelin and 0.5%–1% of peripheral 
nervous system myelin [31]. CNP catalyzes the hydrolysis of 2′,3′ -cyclic nucleotides to form the 
corresponding 2′-monophosphates. CNP has been identified as an integral protein of myelin, produced 
by OLs in the CNS [31–33]. Although this enzyme has also been observed in non-myelin membranes 
derived from various organs, including the liver, thymus, adrenal glands, kidney, heart, and skeletal 
muscle, the levels of the enzymatic activity are significantly lower than those in the CNS [33–35]. 
Therefore, CNPase is an excellent marker for myelinogenesis in both the CNS and PNS. In the present 
work, this marker facilitated the identification of cells that evolved from the Olig2 stage to a more 
mature stage, and this transition allowed us to observe the direct effect of TSC1 as a neuroprotector of 
the Olig2-existing population at the time of the excitotoxic insult, as these cells appeared to move 
forward in the OL lineage. 
4.2. TSC1 as Regulator of Myelination 
OL development is critically dependent on the presence of extracellular trophic factors.  
Several key factors have been identified through the study of myelin mutant animals and cell culture 
studies [36]. We previously showed that normal OLs synthesize and secrete Tf, whose levels are 
significantly reduced in the CNS of myelin mutant animals, such as the md rat, a PLP mutant [19] and 
the Long Evans shaker (LES) rat, a MBP mutant [37,38]. Because of the inadequate expression levels 
of Tf in OLs, while normal levels are maintained in the epithelial cells of the choroid plexus, OL 
maturation and myelination are inefficiently supported [37]. In addition, we have demonstrated that, by 
restoring Tf levels in the md brain at P5, endogenous OLs were mature and formed thin myelin sheaths 
within 14 days [20]. Similar studies using wild-type animals have shown that increasing Tf levels 
through intrathecal injection results in premature OL maturation and myelination [39,40]. This result 
was also confirmed through Tf over-expression in the brain of transgenic mice [41], demonstrating the 
important role that Tf plays on myelinogenesis and maintenance. Another factor impacting OL 
development is insulin growth factor-1 (IGF-1). IGF-1 is a pleiotropic factor with diverse roles in the 
CNS [42]. IGF-1 is a potent promoter of proliferation of neural precursor cells and promotes subsequent 
steps in the differentiation of neurons, astrocytes and oligodendroctyes. In addition to proliferation, 
IGF-1 has been shown to promote myelination [43,44]. IGF-1 is widely distributed in the fetal and 
neonatal CNS, but it is restricted in the adult CNS [45]. Similarly, IGF-1 receptor expression is 
heterogeneous during early stages of CNS development, but the expression levels decline  
postnatally [46] reaching low levels in the aging brain. Furthermore, a partial deletion of the IGF-1 
gene results in intrauterine growth failure and severe post-natal growth delays and intellectual 
disabilities [47]. Based on these facts, the present work was performed to test the potential of TSC1 to 
ameliorate white matter injury after excitotoxicity, as one of many components of PVL. The results 
showed a beneficial effect on the survival of pre-existing CNPase-positive OLs and the proliferation of 
these cells in the presence of a single injection of TSC1. Similar to studies performed with the md 
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mutant rat, TSC1 triggered both cell proliferation in the SVZ and the migration of Olig2-positive cells 
into the CC and CPu, where these cells are expected to myelinate naked axons. These results confirm 
that TSC1 is also beneficial for the premature neonate, conferring trophic support and perhaps 
mimicking a non-injured postnatal microenvironment with a niche that rescues the cells that form the 
white matter. Moreover, we determined that there is a time window between the insult and the 
administration of TSC1, where the results are optimized by maximizing the total number of OLs 
participating in white matter formation and the restoration of CNS function. 
4.3. Modeling and Rescue of Perinatal White Matter Damage 
The neonatal brain is a rapidly changing structure, developing glia and synapses. Because neural 
connections are still developing at birth and myelination is in its most active period, many medications 
for treatment and protection in the adult CNS are ineffective and could even be deleterious, as some 
adult treatments are toxic to neonatal brains [48]. In addition to preventing or delaying premature birth, 
which is considered to be the most important step in reducing the risk of PVL, no treatments have been 
approved for use in human PVL patients. Nonetheless, significant strides have been made to develop 
treatments for the protection of the nervous system. Researchers have examined the potential of 
synthetic neuroprotection to minimize the extent of these lesions in young patients exposed to ischemic 
conditions [28]. In this study, the effects of NMDA were less severe in the presence of TSC1,  
sparing brain tissue and reducing ventriculomegaly through the neuroprotection of pre-existing  
Olig2-expressing OLPs, CNPase-expressing OLs and medium-sized spiny neurons. Moreover, brains 
treated with NMDA in the presence of TSC1 did not show the upregulation in the expression of heat 
shock protein 90 (HSP-90). Like other HSPs, the molecular chaperone HSP-90 is involved in the 
folding, stabilization and binding of many proteins and is essential for maintaining the integrity of 
many signaling cascade pathways in response to cellular stress through aberrant expression and/or 
mutation [49,50]. HSP-90 was first isolated after extracting proteins from cells under various stresses, 
including heat, dehydration or other stressors that induce protein denaturation [51]. Moreover,  
HSP-90 also has essential functions in unstressed cells. Pratt and colleagues reported that monoclonal 
antibodies raised against glucocorticoid receptor (GR) identified the receptor and a 90 kD protein  
that cross-reacted with antibodies raised against HSP-90 [52], thus identifying HSP-90 as a steroid 
hormone receptor chaperone. Steroid hormone receptors are a class of transcription factors activated 
through binding to steroid agonists and were some of the first proteins actively studied as HSP-90 clients. 
Since then, HSP-90 has been shown to bind strongly to the apo-form of many steroid hormone receptors, 
including estrogen and androgen receptors [53]. It is now understood that HSP-90-dependent receptors 
require HSP-90 to bind to steroids [54]. Moreover, HSP-90 mediates steroid receptor maturation, and 
ATP hydrolysis through HSP-90 is required for efficient protein maturation [55]. Steroid binding 
controls the activity of all steroid receptors, and for HSP-90-dependent receptors, this step requires 
HSP-90 activity. When HSP-90 is inhibited, heat shock factor-1 (HSF-1) is activated, leading to the 
subsequent activation of protective stress-induced HSPs, such as HSP-70 [56,57]. The pharmacological 
induction of HSF1 through HSP-90 inhibitors in cell culture and animal models is protective against 
the toxicity induced through pathogenic proteins, ameliorating abnormal transgenic phenotypes in animal 
models and suppressing protein aggregate formation in several models of neurodegeneration [56,57]. 
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Thus, HSP-90 inhibition is therapeutically effective by specifically degrading misfolded or mutated 
client proteins that contribute to disease pathology. HSP-90 inhibitors, such as 17-AAG and radicicol, 
have similar neuroprotective effects as those of HSF-1 and HSP-70 up-regulation [58,59]. The  
blood-brain barrier permeability presents a limitation [60,61]. 17-AAG is currently in phase II trials as 
an antitumor compound [62,63], showing neuroprotective effects in preclinical models of Huntington's 
disease and spinocerebellar ataxias [57,59]. Here, NMDA induced the upregulation of HSP-90 in the 
white matter, but in the presence of TSC1, NMDA did not induce HSP-90 expression, suggesting that 
TSC1 plays a role not only on OLP survival and migration but also in regulating HSP-90 expression in 
white matter regions. Our data from the electrophysiology experiments showed that striatal MSNs 
were also protected by TSC1, indicating that several cell types benefit from the neuroprotective effects 
of this compound. In Huntington’s disease, MSNs are particularly vulnerable to the mutation, and the 
mechanism of cell death involves excitotoxic mechanisms [64]. If NMDA receptors are more sensitive 
in this disease, then the local administration of TSC1 could serve as a neuroprotective strategy. 
The purpose of this study was to examine the potential therapeutic effects of TSC1 after the 
deleterious effects of glutamate excitotoxicity, and therefore, we did not address the potential 
mechanisms of action of this cocktail. Studies are currently underway to elucidate the mechanisms 
underlying the actions of TSC1. 
5. Conclusions 
White matter loss following an excitotoxic insult is not totally irreversible in premature neonates, 
and the attenuation of the early events with a single intervention with TSC1 administered simultaneously 
or at 3 days after the NMDA injection reduced brain tissue loss (1) by protecting pre-existing 
committed Olig2 and CNPase-positive OLs; (2) by enhancing cell proliferation and progression 
towards mature, functional OLs; and (3) through TSC1. Moreover, striatal MSNs were also protected. 
Therefore, TSC1 is the first promising intervention to alleviate perinatal white matter loss and to 
prevent long-term disabilities, such as cerebral palsy and intellectual disabilities. 
Treatment Challenges and Future Directions 
Currently, we propose that a single dose of TSC1 would be necessary and sufficient to mitigate cell 
loss and the enlargement of the ventricle after excitotoxicity. We also defined a developmental window 
in which the effects of TSC1 are beneficial and demonstrated that even three days after the insult 
caused by NMDA there is some benefit conferred to the forming white matter. Nonetheless,  
the simultaneous injection proved to provide the most benefit in terms of preventing tissue loss and 
enhancing survival of existing progenitors at the time of the insult with a concomitant reduction of 
ventricular enlargement. These results indicate that the sooner the intervention the more extensive 
benefit will be conferred to neural progenitors. Thus, after premature birth, the time at which a single 
TSC1 dose is administered may determine the lifelong impact on white matter formation and function 
of the CNS in the premature neonate. At present, the main challenge is to deliver the treatment  
in a non-invasive manner without decreasing its efficacy. We are currently studying various modes  
of intervention. 
  
Brain. Sci. 2013, 3 1478 
 
Acknowledgments 
This work was funded in part by a National Multiple Sclerosis Society grant, NICHD grant 
HD06576 and HD004612 (MSL and CC). 
Conflicts of Interest 
The authors declare no conflict of interest. 
References 
1. Nave, K.A. Myelination and the trophic support of long axons. Nat. Rev. Neurosci. 2010, 11, 
275–283. 
2. Blumenthal, I. Periventricular leucomalacia: A review. Eur. J. Pediatr. 2004, 163, 435–442. 
3. Du Plessis, A.J.; Volpe, J.J. Perinatal brain injury in the preterm and term newborn. Curr. Opin. 
Neurol. 2002, 15, 151–157. 
4. Goldberg, M.P.; Ransom, B.R. New light on white matter. Stroke 2003, 34, 330–332. 
5. Deng, W. Neurobiology of injury to the developing brain. Nat. Rev. Neurol. 2010, 6, 328–336. 
6. Dammann, O.; Leviton, A. Does prepregnancy bacterial vaginosis increase a mother’s risk of 
having a preterm infant with cerebral palsy? Dev. Med. Child Neurol. 1997, 39, 836–840. 
7. Dammann, O.; Leviton, A. Maternal intrauterine infection, cytokines, and brain damage in the 
preterm newborn. Pediatr. Res. 1997, 42, 1–8. 
8. Volpe, J.J. Neurobiology of periventricular leukomalacia in the premature infant. Pediatr. Res. 
2001, 50, 553–562. 
9. Brunssen, S.H.; Harry, G.J. Diffuse white matter injury and neurologic outcomes of infants born 
very preterm in the 1990s. J. Obstet. Gynecol. Neonatal Nur. 2007, 36, 386–395. 
10. Back, S.A.; Rivkees, S.A. Emerging concepts in periventricular white matter injury. Semin. 
Perinatol. 2004, 28, 405–414. 
11. Hagberg, H.; Peebles, D.; Mallard, C. Models of white matter injury: Comparison of infectious, 
hypoxic-ischemic, and excitotoxic insults. Ment. Retard. Dev. Disabil. Res. Rev. 2002, 8, 30–38. 
12. Mesples, B.; Plaisant, F.; Fontaine, R.H.; Gressens, P. Pathophysiology of neonatal brain lesions: 
Lessons from animal models of excitotoxicity. Acta Paediatr. 2005, 94, 185–190. 
13. Rees, S.; Inder, T. Fetal and neonatal origins of altered brain development. Early Hum. Dev. 2005, 
81, 753–761. 
14. Karadottir, R.; Cavelier, P.; Bergersen, J.H.; Attwell, D. NMDA receptors are expressed in 
oligodendrocytes and activated in ischaemia. Nature 2005, 438, 1162–1166. 
15. Salter, M.G.; Fern, R. NMDA receptors are expressed in developing oligodendrocyte processes 
and mediate injury. Nature 2005, 438, 1167–1171. 
16. Kumar, S.; Macklin, W.B.; Gordon, M.N.; Espinosa de los Monteros, A.; Cole, R.; Scully, S.A.; 
de Vellis, J. Transcriptional regulation studies of myelin associated genes in md mutant rats.  
Dev. Neurosci. 1990, 12, 316–325. 
17. Espinosa de los Monteros, A.; Kumar, S.; Scully, R.; Cole, R.; de Vellis, J. Transferrin gene 
expression and secretion by rat brain cells in vitro. J. Neurosci. Res. 1990, 25, 576–580. 
Brain. Sci. 2013, 3 1479 
 
18. Espinosa de los Monteros, A.; de Vellis, J. Myelin basic protein and transferrin characterize 
different subpopulations of oligodendrocytes in rat primary glial cultures. J. Neurosci. Res. 1988, 
21, 181–187. 
19. Espinosa de los Monteros, A.; Zhang, M.; Gordon, M.N.; Kumar, S.; Scully, S.; de Vellis, J.  
The myelin-deficient rat mutant: Partial recovery of oligodendrocyte maturation in vitro.  
Dev. Neurosci. 1990, 12, 326–339. 
20. Espinosa de los Monteros, A.; Kumar, S.; Zhao, P.; Huang, J.C.; Nazarian, R.; Pan, T.; Scully, S.; 
Chang, R.; de Vellis, J. Transferrin is an essential factor for myelination. Neurochem. Res. 1999, 
24, 235–248. 
21. Espinosa-Jeffrey, A.; Zhao, P.M.; Awosika, O.; Huang, A.; Chang, R.; de Vellis, J. Transferrin 
regulates transcription of the MBP gene and its action synergizes with IGF-1 to enhance 
myelinogenesis in the md rat. Dev. Neurosci. 2002, 24, 227–241. 
22. Yamaguchi, M.; Saito, H.; Suzuki, M.; Mori, K. Visualization of neurogenesis in the central 
nervous system using nestin promoter-GFP transgenic mice. Neuroreport 2000, 11, 1991–1996. 
23. Espinosa-Jeffrey, A.; Zhao, P.; Awosika, W.; Wu, N.; Macias, F.; Cepeda, C.; Levine, M.;  
de Vellis, J. Activation, proliferation and commitment of endogenous, stem/progenitor cells to the 
oligodendrocyte lineage by a combination of neurotrophic factors in a rat model of 
dysmyelination. Dev. Neurosci. 2006, 28, 488–498. 
24. Espinosa de los Monteros, A.; Zhan, M.; Gordon, G.M.; Aymie, M.; Vellis, J. Transplantation of 
cultured premyelinating oligodendrocytes into normal and myelin-deficient rat brain. Dev. Neurosci. 
1992, 14, 98–104. 
25. Ma, J.; Matsumoto, M.; Tanaka, K.; Takebayashi, H.; Ikenaka, K. An animal model for late onset 
chronic demyelination disease caused by failed terminal differentiation of oligodendrocytes. 
Neuron Glia Biol. 2005, 2, 81–91. 
26. Espinosa-Jeffrey, A.; Hitoshi, S.; Zhao, P.; Awosika, O.; Agbo, C.; Olaniyan, E.; Garcia, J.; 
Valera, R.; Thomassian, A.; Chang, W.R.; et al. Functional central nervous system myelin repair 
in an adult mouse model of demyelination caused by proteolipid protein overexpression.  
J. Neurosci. Res. 2010, 88, 1682–1694. 
27. Mallory, F.B. Pathological Technique: A Practical Manual for Workers in Pathological 
Histology Including Directions for the Performance of Autopsies and for Microphotography; 
W.B. Saunders: Philadelphia, PA, USA, 1942; p. 237. 
28. Fleiss, B.; Gressens, P. Tertiary mechanisms of brain damage: A new hope for treatment of 
cerebral palsy? Lancet Neurol. 2012, 11, 556–566. 
29. Espinosa de los Monteros, A.; Baba, H.; Zhao, P.M.; Pan, T.; Chang, R.; de Vellis, J.; Ikenaka, K. 
Remyelination of the adult demyelinated mouse brain by grafted oligodendrocyte progenitors and 
the effect of B-104 cografts. Neurochem. Res. 2001, 26, 673–682. 
30. Miller, S.P.; Ferriero, D.M. From selective vulnerability to connectivity: Insights from newborn 
brain imaging. Trends Neurosci. 2009, 32, 496–505. 
31. Sprinkle, T.J. 2′,3′-Cyclic nucleotide 3′-phosphodiesterase, an oligodendrocyte-Schwann cell and 
myelin-associated enzyme of the nervous system. Crit. Rev. Neurobiol. 1989, 4, 235–301. 
Brain. Sci. 2013, 3 1480 
 
32. Vogel, U.S.; Thompson, R.J. Molecular structure, localization, and possible functions of the 
myelin-associated enzyme 2′,3′-cyclic nucleotide 3′-phosphodiesterase. J. Neurochem. 1988, 50, 
1667–1677. 
33. Giulian, D.; Moore, S. Identification of 2′,3′-cyclic nucleotide 3′-phosphodiesterase in the 
vertebrate retina. J. Biol. Chem. 1980, 255, 5993–5995. 
34. Dreiling, C.E.; Schilling, R.J.; Reitz, R.C. 2′,3′-Cyclic nucleotide 3′-phosphohydrolase in rat liver 
mitochondrial membranes. Biochim. Biophys. Acta 1981, 640, 114–120. 
35. Weissbarth, S.; Maker, H.S.; Raes, I.; Brannan, T.S.; Lapin, E.P.; Lehrer, G.M. The activity of 
2′,3′-cyclic nucleotide 3′-phosphodiesterase in rat tissues. J. Neurochem. 1981, 37, 677–680. 
36. Baumann, N.; Pham-Dinh, D. Biology of oligodendrocyte and myelin in the mammalian central 
nervous system. Physiol. Rev. 2001, 81, 871–927. 
37. Bartlett, W.P.; Li, X.S.; Connor, J.R. Expresion of transferring mRNA in the CNS of normal and 
jimpy mice. J. Neurochem. 1991, 57, 318–322. 
38. Barlett, W.P.; Li, X.S.; Williams, M.; Benkovic, S. Localization of insulin-like growth factor-1 
mRNA in murine central nervous system during postnatal development. Dev. Biol. 1991, 147, 
239–250. 
39. Escobar, O.P.; Bongarzone, E.R.; Soto, E.F.; Pasquini, J.M. Single intracerebral injection of  
apo-transferrin in young rats induces increased myelination. Dev. Neurosci. 1994, 16, 248–254. 
40. Adamo, A.M.; Paez, P.M.; Escobar-Cabrera, O.R.; Wolfson, M; Franco, P.G.; Pasquini, J.M.; 
Soto, E.F. Remyelination after cuprizone-induced demyelination in the rat is stimulated by 
apotransferrin. Exp. Neuol. 2006, 198, 519–529. 
41. Saleh, M.C.; Espinosa de los Monteros, A.; de Arriba Zerpa, G.A.; Fontaine, I.; Piaud, O.; 
Djordjijevic, D.; Baroukh, N.; Garcia Otin, A.L.; Ortiz, E.; Lewis, S.; et al. Myelination and 
motor coordination are increased in transferrin transgenic mice. J. Neurosci. Res. 2003, 72,  
587–594. 
42. Fernandez, A.M.; Torres-Alemán, I. The many faces of insulin-like peptide signalling in the brain. 
Nat. Rev. Neurosci. 2012, 13, 225–239. 
43. McMorris, F.A.; Duboi-Dalcq, M. Insulin-like growth factor I promotes cell proliferation and 
oligodendroglial commitment in rat glial progenitor cells developing in vitro. J. Neurosci. Res. 
1988, 21, 199–209. 
44. McMorris, F.A.; McKinnon, R.D. Regulation of oligodendrocyte development and CNS myelination 
by growth factors: Prospects for therapy of demyelinating disease. Brain Pathol. 1996, 6, 313–329. 
45. Werner, H.; Woloschak, M.; Adamo, M.; Shen-Orr, Z.; Roberts, C.T., Jr.; LeRoith, D. 
Developmental regulation of the rat insulin-like growth factor I receptor gene. Proc. Natl. Acad. 
Sci. USA 1989, 86, 7451–7455. 
46. Madathil, S.K.; Evans, H.N.; Saatman, K.E. Temporal and regional changes in IGF-1/IGF-1R 
signaling in the mouse brain after traumatic brain injury. J. Neurotrauma 2010, 27, 95–107. 
47. Zapf, J.; Froesch, E.R. Insulin‐like growth factor I actions on somatic growth. Compr. Physiol. 
2011, 24, 663–699. 
48. Rosenberg, P.A.; Dai, W.; Gan, X.D.; Ali, S.; Fu, J.; Back, S.A; Sanchez, R.M.; Segal, M.M.; 
Follett, P.L.; Jensen, F.E.; et al. Mature myelin basic protein-expressing oligodendrocytes are 
insensitive to kainate toxicity. J. Neurosci. Res. 2003, 71, 237–245. 
Brain. Sci. 2013, 3 1481 
 
49. Marcu, M.G.; Schulte, T.W.; Neckers, L. Novobiocin and related coumarins and depletion of heat 
shock protein 90-dependent signaling proteins. J. Natl. Cancer Inst. 2000, 92, 242–248. 
50. Xiao, X.; Zuo, X.; Davis, A.A.; McMillan, D.R.; Curry, B.B.; Richardson, J.A.; Benjamin, I.J. 
HSF1 is required for extra-embryonic development, postnatal growth and protection during 
inflammatory responses in mice. EMBO J. 1999, 18, 5943–5952. 
51. Prodromou, C.; Panaretou, B.; Chohan, S.; Siligardi, G.; O’Brien, R.; Ladbury, J.E.; Roe, S.M.; 
Piper, P.W.; Pearl, L.H. The ATPase cycle of Hsp90 drives a molecular ‘clamp’ via transient 
dimerization of the N-terminal domains. EMBO J. 2000, 19, 4383–4392. 
52. Panaretou, B.; Siligardi, G.; Meyer, P.; Maloney, A.; Sullivan, J.K.; Singh, S.; Millson, S.H.; 
Clarke, P.A.; Naaby-Hansen, S.; Stein, R.; et al. Activation of the ATPase activity of hsp90 by the 
stress-regulated cochaperone aha1. Mol. Cell 2002, 10, 1307–1318. 
53. Spence, R.D.; Hamby, M.E.; Umeda, E.; Itoh, N.; Du, J.; Wisdom, S.; Cao, Y.; Bondar, G.;  
Lam, J.; Ao, Y.; et al. Neuroprotection mediated through estrogen receptor-alpha in astrocytes. 
Proc. Natl. Acad. Sci. USA 2011, 108, 8867–8872. 
54. Passinen, S.; Valkila, J.; Manninen, T.; Syvala, H.; Ylikomi, T. The C-terminal half of Hsp90 is 
responsible for its cytoplasmic localization. Eur. J. Biochem. 2001, 268, 5337–5342. 
55. Picard, D.; Yamamoto, K.R. Two signals mediate hormone-dependent nuclear localization of the 
glucocorticoid receptor. EMBO J. 1987, 6, 3333–3340. 
56. Dickey, C.A.; Eriksen, J.; Kamal, A.; Burrows, F.; Kasibhatla, S.; Eckman, C.B.; Hutton, M.; 
Petrucelli, L. Development of a high throughput drug screening assay for the detection of changes 
in tau levels—Proof of concept with HSP90 inhibitors. Curr. Alzheimer Res. 2005, 2, 231–238. 
57. Fujikake, N.; Nagai, H.; Popiel, H.A.; Okamoto, Y.; Yamaguchi, M.; Toda, T. Heat shock 
transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration 
through induction of multiple molecular chaperones. J. Biol. Chem. 2008, 283, 26188–26197. 
58. Auluck, P.K.; Meulener, M.C.; Bonini, N.M. Mechanisms of suppression of α-synuclein 
neurotoxicity by geldanamycin in drosophilia. J. Biol. Chem. 2005, 280, 2873–2878. 
59. Waza, M.; Adachi, H.; Katsuno, M.; Minamiyama, M.; Tanaka, F; Sobue, G. Alleviating 
neurodegeneration by an anticancer agent: An Hsp90 inhibitor (17-AAG). Ann. N. Y. Acad. Sci. 
2006, 1086, 21–34. 
60. Chiosis, G.; Tao, H. Purine-scaffold Hsp90 inhibitors. IDrugs 2006, 9, 778–782. 
61. Taldone, T.; Gozman, A.; Maharaj, R.; Chiosis, G. Targeting Hsp90: Small-molecule inhibitors 
and their clinical development. Curr. Opin. Pharmacol. 2008, 8, 370–374. 
62. Heath, E.L.; Gaskins, M.; Pitot, H.C.; Pili, R.; Tan, W.; Marschke, R.; Liu, G.; Hillman, D.; 
Sarkar, F.; Sheng, S.; et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in 
patients with hormone-refractory metastatic prostate cancer. Clin. Prostate Cancer 2005, 4,  
138–141. 
63. Ramanathan, R.K.; Trump, D.L.; Eiseman, J.L.; Belani, C.P.; Agarwala, S.S.; Zuhowski, E.G.; 
Lan, J.; Potter, D.M.; Ivy, S.P.; Ramalingam, S.; et al. Phase I pharmacokinetic-pharmacodynamic 
study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor 
of heat shock protein 90, in patients with refractory advanced cancers. Clin. Cancer Res. 2005, 11, 
3385–3391. 
Brain. Sci. 2013, 3 1482 
 
64. DiFiglia, M. Excitotoxic injury of the neostriatum: A model for Huntington’s disease.  
Trends Neurosci. 1990, 7, 286–289. 
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
